Core D In vitro Screening
Core D In vitro Screening
批准号:
9923599
负责人:
BARRY Neal KREISWIRTH
金额:
$37.44万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
Acinetobacter baumanniiAfrican Green MonkeyAnti-Bacterial AgentsAntibiotic ResistanceAntibiotic susceptibilityAreaBacillus anthracisBacillus cereusBacteriaBiological AssayBurkholderia cepaciaCell LineCellsClinicalCollaborationsCollectionComputer softwareDataDevelopmentDrug CombinationsDrug resistanceESKAPE pathogensEnterobacterEnterococcus faeciumEpithelialEpitheliumFrancisella tularensisFrequenciesGenerationsHospitalsIn VitroIndividualInfectionInhibition of Cell ProliferationKidneyKlebsiella pneumoniaeLaboratoriesMammalian CellMetabolicMethodologyMicrobial BiofilmsMinimum Inhibitory Concentration measurementModelingMolecularMulti-Drug ResistanceMusMycobacterium abscessusMycobacterium fortuitumMycobacterium marinumMycobacterium smegmatisMycobacterium tuberculosisNeisseria gonorrhoeaeNew JerseyNew YorkOrganismPathogenicityPharmaceutical ChemistryPharmaceutical PreparationsPhasePhenotypePredispositionPreventionPrivatizationPseudomonas aeruginosaResistanceResistance profileResourcesSerumStaphylococcus aureusStatistical Data InterpretationSystemTestingTherapeuticTimeVariantYersinia pestisbacterial resistancecytotoxicitydata sharingdrug discoveryexperienceexperimental studyin vitro Assayinnovationmacrophagemetropolitanmicrobialmutantmycobacterialpathogenprogramsresistance mechanismresponsescreeningsuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
The microbial In Vitro Screening (IVS) Core will provide comprehensive susceptibility testing
encompassing a range of assays for candidate compounds of the five projects. The projects
represent various stages in development and require individual consideration. However, a
common thread through all 5 projects is the requirement for whole cell screening. The resources
and expertise of the IVS Core include macrophage infection model and intracellular susceptibility,
concentration-dependent killing versus time-dependent killing, small colony variants, anti-biofilm
efficacy, serum shift experiments, stationary phase or “one hundred day old” cultures, resistant
mutant generation and analysis, and drug combination analysis. Drug response relationships to
assess mutant formation/prevention and other advanced analysis are also available. Compound
purity will be confirmed working in conjunction with the Medicinal Chemistry Core (Core B). Data
conformity and storage will be handled and shared using the Collaborative Drug Discovery, Inc.
software program (see Data Sharing). The organisms in the Screening Core’s collection include
twenty-eight species of pathogens. The laboratories of Dr. Connell and Dr. Barry Kreiswirth
(PHRI) provide extensive collections of clinical strains, well characterized for antibiotic resistance,
assembled in collaboration with private, public and VA hospitals in the New York/New Jersey
metropolitan area, as well as hospitals throughout the world, that will serve in later stages of the
project to define resistance profiles. BSL2, BSL3 and Select Agent BSL3 laboratories are
provided for the safe use of this extensive strain collection. The team assembled to carry out
these in vitro assays has a combined experience of over 65 years in bacterial drug discovery and
analysis of antibiotic susceptibility and resistance. The group's medium throughput experience
with high precision and fast turnaround is a significant and essential contribution to the overall
project’s success.
!
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The molecular basis of the carbapenem resistance epidemic
-
批准号:10065482
-
项目类别:
-
资助金额:$66.74万
-
财政年份:2019
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
Core D In vitro Screening
-
批准号:10613890
-
项目类别:
-
资助金额:$53.99万
-
财政年份:2019
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
A dual-beta-lactam strategy for treating multidrug resistant M abscessus
-
批准号:10228661
-
项目类别:
-
资助金额:$81.28万
-
财政年份:2019
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
Core D In vitro Screening
-
批准号:10394988
-
项目类别:
-
资助金额:$37.68万
-
财政年份:2019
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
Unraveling colistin resistance in Klebsiella pneumoniae
-
批准号:9919087
-
项目类别:
-
资助金额:$22.14万
-
财政年份:2019
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
A dual-beta-lactam strategy for treating multidrug resistant M abscessus
-
批准号:10457876
-
项目类别:
-
资助金额:$80.99万
-
财政年份:2019
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
A rapid molecular approach to determine PZA susceptibility
-
批准号:8603441
-
项目类别:
-
资助金额:$0.8万
-
财政年份:2013
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
A rapid molecular approach to determine PZA susceptibility
-
批准号:8709716
-
项目类别:
-
资助金额:$22.75万
-
财政年份:2013
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
A rapid molecular approach to determine PZA susceptibility
-
批准号:8667400
-
项目类别:
-
资助金额:$20.2万
-
财政年份:2013
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of the epidemic blaKPC gene Klebsiella
-
批准号:8434219
-
项目类别:
-
资助金额:$7.63万
-
财政年份:2011
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of the epidemic blaKPC gene Klebsiella
-
批准号:8240409
-
项目类别:
-
资助金额:$53.63万
-
财政年份:2011
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of the epidemic blaKPC gene Klebsiella
-
批准号:8711600
-
项目类别:
-
资助金额:$76.22万
-
财政年份:2011
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of the epidemic blaKPC gene Klebsiella
-
批准号:8106830
-
项目类别:
-
资助金额:$23.72万
-
财政年份:2011
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of the epidemic blaKPC gene Klebsiella
-
批准号:8839707
-
项目类别:
-
资助金额:$54.48万
-
财政年份:2011
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of the epidemic blaKPC gene Klebsiella
-
批准号:8610873
-
项目类别:
-
资助金额:$56.45万
-
财政年份:2011
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of the carbapenem resistance epidemic
-
批准号:9238126
-
项目类别:
-
资助金额:$64.76万
-
财政年份:2011
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
The molecular basis of epidemic blaKPC Klebsiella pneumoniae and Enterobacteriace
-
批准号:8148137
-
项目类别:
-
资助金额:$55.84万
-
财政年份:2010
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
Analysis of XDR-TB and MDR-TB strains: safety, diagnosis and pathogenesis
-
批准号:8497764
-
项目类别:
-
资助金额:$14.23万
-
财政年份:2009
-
负责人:BARRY Neal KREISWIRTH
-
依托单位:
海外基金